Source comparison
Step 2: Dose CJC-1295 at 30–60 mcg/kg Weekly Based on DAC vs Modified Formulation
CJC-1295 exists in two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and modified CJC-1295 without DAC, sometimes labelled as 'MOD GRF 1-29'. The DAC modification extends the peptide's half-life from approximately 30 minutes to 6–8 days by preventin
This comparison does not assign a generated winner or score.
- CJC-1295 exists in two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and modified CJC-1295 without DAC, sometimes labelled as 'MOD GRF 1-29'. The DAC modification extends the peptide's half-life from approximately 30 minutes to 6–8 days by preventing enzymatic degradation. This single structural change fundamentally alters dosing frequency and fat loss kinetics. Research models using CJC-1295 with DAC administered doses of 30–60 mcg/kg once weekly, producing sustained GH and IGF-1 elevation across the entire dosing interval. Modified CJC-1295 without DAC requires more frequent administration. Typically 100–200 mcg per dose, 2–3 times daily. Because the peptide clears rapidly and must be timed around natural GH pulses to amplify endogenous secretion.
- For a 180-pound (82kg) researcher, the weekly DAC protocol would be approximately 2.5–5mg total dose per week, administered as a single subcutaneous injection. Modified CJC-1295 protocols in the same individual would use 100–200 mcg per injection, dosed before bed and optionally upon waking, totaling 1.4–4.2mg per week distributed across multiple administrations. The fat loss timeline differs: DAC forms produce gradual, sustained lipolysis over 8–16 weeks as GH remains elevated continuously, while modified forms create intermittent GH spikes that require stricter fasting windows to maximize fat oxidation.
- Dosing above 60 mcg/kg weekly with DAC forms does not proportionally increase fat loss. It saturates GHRH receptors and triggers negative feedback loops that blunt endogenous GH secretion. Clinical observation in endocrinology research suggests that moderate, sustained elevation outperforms supraphysiological spikes for body recomposition, likely because extreme GH levels increase insulin resistance and promote glucose sparing rather than fat utilization. The dose-response curve for CJC-1295 is not linear.